Samsung Biologics Co.,Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 106,563.77 million compared to KRW 82,273.21 million a year ago. Net income was KRW 240,366.71 million compared to KRW 129,164.03 million a year ago. Basic earnings per share from continuing operations was KRW 3,377 compared to KRW 1,815 a year ago. Diluted earnings per share from continuing operations was KRW 3,376 compared to KRW 1,815 a year ago. Basic earnings per share was KRW 3,377 compared to KRW 1,815 a year ago.
For the nine months, sales was KRW 253,847.3 million compared to KRW 156,698.93 million a year ago. Net income was KRW 567,007.76 million compared to KRW 428,147.03 million a year ago. Basic earnings per share from continuing operations was KRW 7,967 compared to KRW 6,181 a year ago. Diluted earnings per share from continuing operations was KRW 7,967 compared to KRW 6,174 a year ago. Basic earnings per share was KRW 7,967 compared to KRW 6,181 a year ago.